Other Corporate Information

iZafe Group has successfully completed the implementation of Dosell in Spain and ships first 30 units

iZafe Group AB ("iZafe Group") is pleased to announce the successful implementation of their medication robot, Dosell, in Spain. The company has now completed all necessary technical integrations and adjustments required to launch Dosell in the Spanish market after a series of successful integrations. These adaptations encompassed both technical refinements to the Dosell unit itself and the platform, as well as extensive developments and adjustments by our collaboration partner.

As a significant step forward, iZafe Group has now delivered the first 30 Dosell units to Ti-Medi to commence practical testing of the customer journey over the nexts months. This phase of the pilot program will contribute to ensuring a seamless launch and customer experience. Upon successful completion of the testing phase, commercial sales will commence after the turn of the year, in accordance with the previously communicated plan.

"We are thrilled to announce the successful delivery of our cutting-edge pharmaceutical robot, Dosell, to the thriving market of Spain. This marks a significant milestone in our mission to helping patients taking the right medication at the right time in yet another country. We are committed to providing innovative solutions that empower healthcare professionals and improve patient care. This achievement is a testament to the hard work and dedication of our team, and we look forward to making a positive impact on the healthcare landscape in Spain and beyond." Says Anders Segerström, CEO of iZafe Group AB

"We're excited to announce a big change in our business model as we start focusing on serving individual consumers (B2C). This shift is a major milestone for us, and we know there's a lot of work to do. We're staying dedicated to working closely with our trusted pharmacy partners to make sure our pilot program gets the attention and resources it needs. We're confident that by leveraging our current partnerships and industry knowledge, this initiative will be a valuable learning experience. We're teaming up with iZafe to bring innovative solutions to the B2C market in the MDS industry." Rafa Tibau, CIO of Ti-Medi.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution and the connected dose bag Pilloxa. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group has successfully completed the implementation of Dosell in Spain and ships first 30 units

Rafa Ti Medi

iZafe Group’s CEO Anders Segerström acquires an additional 208,333 shares.

iZafe Group's CEO, Anders Segerström, has today acquired an additional 208,333 B-shares in the company. The transaction was completed at a total value of 50,000 SEK, equivalent to 0.24 SEK per share. With this latest purchase, Anders Segerström now holds a total of 1,598,773 B-shares in iZafe Group.

"It is with pleasure and belief that I increase my ownership stake in iZafe Group. This decision reflects my full confidence in our dedicated team and our future potential. Today, we stand on a strong foundation to collectively continue working hard towards creating a successful future for our shareholders, the company, individuals who require multiple medications, society, and healthcare." says Anders Segerström, CEO iZafe Group AB.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group's CEO Anders Segerström acquires an additional 208,333 shares.

Anders Segerstrom

iZafe Group’s new identity is launched to clarify the company’s vision

iZafe group AB (publ.) is proud to present an exciting new development in the company's identity and expression. With the goal of further strengthening its presence on the international scene, the company is today launching an updated logo and design, in parallel with the launch of a new website that is in both Swedish and English.

iZafe's current logo and color language were developed when the company focused on both safety and health. iZafe implements this change to better reflect the company's current vision and direction and make it easier for owners and other stakeholders to get a correct and comprehensive picture of where the company stands and is headed.
The new design captures the company's dedication to developing digital products to ensure the right medication at the right time, while standing as a symbol of precision and care for each individual patient.

At the center of the new logo is a subtle pill shape, surrounded by rings reminiscent of fingerprints. This design highlights the uniqueness of the individual and the company's focus on patients. The clean and elegant lines radiate efficiency and streamlined operations, demonstrating the simplicity and convenience of the automated products and services. The rings expand from the pill like ripples on the water and symbolize change and transformation. The technological elements are emphasized by node-like line endings.

The new logo is complemented by a clean and modern typography, which harmoniously enhances the simplicity and style of the design.

In connection with iZafe receiving great interest internationally, the website is being launched in both Swedish and English and is designed to give visitors a deeper insight into the company's innovative work and commitment to patient safety and medical adherence.

"With the new logo and design, we are taking a powerful step into the future. We are strengthening our commitment to being the leading player in digital services for correct medication. This change reflects our determination to streamline our focus and corporate profile towards our core business. We are ready to shape a new era where we become the natural partner for healthcare companies globally, and our goal is clear – to help people stay healthy and live longer in their own homes.” says Anders Segerström, CEO iZafe Group.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group's new identity is launched to clarify the company's vision

Förklaring Ikon

The Chairman of iZafe Group, Björn Rosengren, acquires an additional 500,000 shares

Today, the Chairman of iZafe Group, Björn Rosengren, has acquired 500,000 Class B shares in the company, valued at 110,000 SEK (0.22 SEK per share.

In addition to today's transaction, Björn Rosengren also acquired 50,000 A-shares last week. Björn Rosengren now holds a total of 2,960,319 B-shares and 50,000 A-shares.

"I am pleased to increase my ownership in iZafe Group, which reflects my belief in the company's vision and potential," says Björn Rosengren. "These acquisitions demonstrate my continued commitment to supporting iZafe Group's strategic goals and creating value for its shareholders."

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafe.se/investor-relations/.

The Chairman of iZafe Group, Björn Rosengren, acquires an additional 500,000 shares

iZafe Group AB ready for the implementation of Dosell in the Netherlands following successful integrations

iZafe Group AB ("iZafe Group") announces today that the company has successfully completed all necessary technical integrations and adaptations to launch its groundbreaking medication robot, Dosell, in the Dutch market. These adaptations have included both technical adjustments in the Dosell device and platform, as well as extensive developments and customizations from our partner.

As a significant step forward, iZafe Group will now deliver 50 Dosell units to test the new customer journey in practice for one month. This phase of the pilot program will contribute to ensuring a smooth launch and customer experience. Following successful testing, the remaining 1,000 units will be delivered gradually throughout the rest of the year, according to the previously communicated plan.

"We are delighted to be part of this collaboration with iZafe Group for the launch of Dosell in the Dutch market. Dosell offers a groundbreaking digital medication robot that complements our existing portfolio of connected healthcare services. We are confident that Dosell will provide a reliable and secure alternative for the medication needs of our healthcare and alarm center clients in the Netherlands. Together, we can fulfill our shared mission of promoting independence and security in the simplest, safest, and most cost-effective way," says Martijn Van Bree, CEO of IVE Ventures.

"We are very pleased to have completed the technical integrations and adaptations for the launch of Dosell in the Dutch market. This marks a significant milestone for us and opens doors to a market known for its commitment to medication in pouches. The selection of Dosell by IVE Ventures after careful evaluation of competitors confirms the great potential of our product on the international stage. We look forward to collaborating with IVE and enabling a safe and efficient medication experience for their clients," says Anders Segerström, CEO of iZafe Group AB.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB ready for the implementation of Dosell in the Netherlands following successful integrations

iZafe opens up more sales channels for Dosell consumer

iZafe Group AB ("iZafe Group") announces today that they are now removing exclusive sales of Dosell via Apoteket.se and are instead opening up to future sales via several sales channels. This after receiving great international impact for their pharmaceutical robot and now having volume commitments from several countries, including the UK, Holland, Portugal and Spain.

iZafe has also started dialogues with several pharmacies regarding selling Dosell as a consumer product and will therefore initially sell Dosell on its own website Dosell.se, before it is gradually sold via more partners. The introductory offer on the hardware remains SEK 499 until the last of May, before the price is raised to SEK 1,999. The monthly fee of SEK 299 will be maintained.

"The launch of the consumer version has been a determining factor in being able to sign the partners we have now started this year with. We are very happy about the great international interest for Dosell and look forward to opening up more sales channels. Our goal is to make Dosell available to as many people as possible who need help managing their medication." says Anders Segerström, CEO of iZafe Group.

For more information about Dosell, visit Dosell.se.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe opens up more sales channels for Dosell consumer

iZafe Group AB gets a new international strategic shareholder

iZafe Group AB ("iZafe Group" or the “Company”) hereby announces that that the Spanish company Ti-Medi has acquired approximately five percent of the shares in the Company, which makes Ti-Medi one of iZafe Group's largest shareholders. Ti-Medi has in total acquired 12,529,309 shares at the price of SEK 0.29 per share through a block deal brokered by Mangold Fondkommission.

Ti-Medi is a global company active in the manufacturing and distribution of technical solutions for compliance in pharmaceutical management. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.
For more information, see Ti-Medi's website, www.ti-medi.com/en.

"Our assessment is that the demand for iZafe Group's products and services will increase in the markets where we operate. We have long been looking for a company that develops and offers its customers precisely these types of services. Therefore, we have decided to invest in iZafe Group and we also hope to be able to find a good collaboration in the future to bring iZafe's products and services into Ti-Medi's product range in order to be able to offer these to our customers," says Marc Tarruell Tibau, co-founder of Ti-Medi

"The company has now gained a new strong and long-term owner that contributes with expertise and a global network. We view this very positively and interpret the investment as proof that iZafe Group's product and operations have support among knowledgeable market colleagues. We look forward to sharing the knowledge that Ti-Medi possesses about distribution in Southern Europe and initiating discussions about a future collaboration", says Anders Segerström, CEO of iZafe Group AB

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

iZafe Group AB gets a new international strategic shareholder

iZafe Group is now also available on the fintech platform Eucaps.com

As part of the internationalization strategy, iZafe Group has entered into a collaboration with the fintech platform eucaps.com. This is to facilitate the dissemination of information and dialogue with existing shareholders and to be able to reach out to new investors outside Sweden's borders.

"Eucap's platform offers opportunities for us at iZafe Group to drive international interest in our share, while at the same time we can easily interact and keep our existing owners updated on our development," says Anders Segerström CEO of iZafe Group AB and continues: "The internationalization of our business has taken off and as a step in the process we want to offer better conditions for international investors to follow our company and our share, which hopefully means increased international attention and new investors."

Eucap's platform offers global transparency and market access for companies in the European small-cap segment, which means, among other things, that companies traded on the Swedish stock exchange First North become accessible to investors from all over Europe. Eucaps ensures that investors have full access to accurate information, reports, stock prices, ownership data, news, etc.

"We are happy that iZafe has chosen to grow with us. Our goal is to make the opportunities in the European small-cap market visible to investors from all over the world. At the same time, we want to prevent market manipulation and create better liquidity and pricing for these companies," says Henrik Wagenius, CEO and founder of Eucaps.

To follow iZafe Group AB in Eucaps go to the following link: https://eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell and SaaS platform Pilloxa with smart pillbox are used to reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

iZafe Group is now also available on the fintech platform Eucaps.com

Warrants of series TO13B were subscribed to approximately 81.7 percent and iZafe Group receives approximately SEK 19.4 million

iZafe Group AB (”iZafe Group” or the ”Company”) today announces the outcome of the exercise of warrants of series TO13B, which were issued in the fourth quarter of 2022. In total, 96,805,841 warrants of series TO13B were exercised, corresponding to approximately 81.7 percent of the total number of outstanding warrants of series TO13B, for subscription of 96,805,841 B-shares at a subscription price of SEK 0.20 per B-share. iZafe Group will receive approximately SEK 19.4 million before issuing costs through the exercise of the warrants of series TO13B.

"I want to start by thanking our shareholders for their great support for iZafe Group, something that is made clear from the outcome of the warrants program. The company is facing a commercial breakthrough with a strong international interest in Dosell which will now be sold in large volumes, something we have been working on for a very long time. At the same time, we have greatly reduced our development costs and with the proceeds from the warrants, our assessment is that the Company's liquidity needs are satisfied up until cash flow positivity. I look very positively at 2023 and the position we are in. I want to thank all our employees, shareholders, and partners who made it possible.” – Anders Segerström, CEO iZafe Group

Background

The subscription period for exercise of the warrants of series TO13B took place from February 23, 2023, up to and including March 8, 2023. The subscription price per B-share for exercising the warrants of series TO13B was set to SEK 0.20.

In total, 96,805,841 warrants of series TO13B were exercised for subscription of 96,805,841 B-shares, meaning that approximately 81.7 percent of all outstanding warrants of series TO13B were exercised for subscription of B-shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to B-shares within approximately three (3) weeks.

Number of shares, share capital and dilution

Through the exercise of the warrants of series TO13B, the number of shares in iZafe Group increases by 96,805,841 B-shares, from 153,780,330 shares (consisting of 600,000 A-shares and 153,180,330 B-shares) to a total of 250,586,171 shares. The share capital will increase by SEK 19,361,168.20 from SEK 30,756,066.00 to SEK 50,117,234.20.

For existing shareholders who did not exercise any warrants of series TO13B, the dilution amounts to approximately 38.6 percent of the number of shares and approximately 37.8 percent of the number of votes in the Company.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

About iZafe Group AB (publ.)

Warrants of series TO13B were subscribed to approximately 81.7 percent and iZafe Group receives approximately SEK 19.4 million

The last day of trading in the warrants of series TO13B in iZafe Group AB is today, March 6, 2023

Today, March 6, 2023, is the last day of trading with the warrants of series TO13B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO13B runs up until March 8, 2023. Each warrant of series TO13B gives the owner the right to subscribe for one (1) new share of series B in iZafe. The exercise price for the warrants of series TO13B is SEK 0.20 per share of series B.

If all the warrants of series TO13B are exercised, the Company will receive approximately SEK 23.7 million before issuing costs. In order to prevent the warrants expiring without value, the holder must actively subscribe for new shares, no later than March 8, 2023. Alternatively, the holder may sell the warrants, no later than today, March 6, 2023. Please be aware that certain nominees may close their subscriptions earlier than March 8, 2023. Complete terms and conditions for the warrants are available on the Company’s website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

The last day of trading in the warrants of series TO13B in iZafe Group AB is today, March 6, 2023